))
Why AI Isn't Ready to Make Medicines
Manage episode 471243453 series 3640924
Content provided by Celesta Capital | Deep Tech Venture Capital Firm. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Celesta Capital | Deep Tech Venture Capital Firm or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Many in venture capital and biopharma are anointing artificial intelligence the savior of drug discovery—but what can AI actually do?
In this eye-opening episode, Michael Marks sits down with Mike Nohaile, CEO of Prellis Biologics, to explore the hype versus reality in AI-enabled drug discovery. Mike details why, despite significant breakthroughs like AlphaFold and recent Nobel Prize win for computational protein design, fully AI-generated medicines still present challenges. He also discusses why we urgently need more effective medicines and details Prellis’ unique system which combines laser printed human organoids and an externalized human immune system with AI, enabling the discovery of fully human antibodies.
If you enjoy this episode, please subscribe and leave us a review on your favorite podcast platform. Sign up for our newsletter at techsurgepodcast.com for exclusive insights and updates on upcoming TechSurge Live Summits.
Links:
Explore Prellis Biologics
Understand AlphaFold, DeepMind’s AI model for predicting protein structures
https://deepmind.google/alphafold
Read about the 2024 Nobel Prize in Chemistry
https://www.nobelprize.org/prizes/chemistry/2024/press-release/
21 episodes
Share
